SHANGHAI & ROTTERDAM, NETHERLANDS & CAMBRIDGE, MA - May 31, 2018 - Harbour BioMed announced today that it has licensed its patented H2L2 fully human antibody discovery platform to Celsius Therapeutics, a newly launched company translating single-cell genomic insights into precision therapeutics. The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV.

Harbour BioMed’s H2L2 transgenic mouse platform enables biotechnology, pharmaceutical companies, and academia to accelerate new drug development by generating fully human monoclonal antibodies. Under the licensing agreement, Celsius Therapeutics has rights to use the H2L2 platform for multiple programs over a multi-year period. Financial details were not disclosed.

“Therapeutic antibody discovery is one of the fastest growing segments of the global pharmaceutical research. More and more approved antibody drugs are fully human antibodies generated from transgenic platforms,” said Dr. Jingsong Wang, CEO of Harbour BioMed. “Harbour’s transgenic platforms, including H2L2 and HCAb for generating heavy chain only antibodies, have been widely used by over forty companies and academic centers. The platforms were engineered to produce high quality and highly diverse, full human antibodies through natural process of in vivo maturation from carefully selected human immunoglobulin transgenes. In the past twelve months, two of the antibodies generated from our H2L2 platform entered into human clinical trials.”

About Harbour BioMed

 
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

 
The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.  

For further information, please refer to www.harbourbiomed.com

About Harbour BioMed

 
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

 
The Company’s proprietary antibody technology platforms Harbour Mice^® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. 

For  more  information, please visit http://harbourantibodies.com.

Contacts

Harbour Antibodies
Timothy Miller
timothy.miller@harbourbiomed.com

Harbour BioMed
Xian Wu
xian.wu@harbourbiomed.com

This Article is published on Business Wire:

Original link: https://www.businesswire.com/news/home/20180531005150/en/Harbour-BioMed-Announces-Multi-Year-Transgenic-Platform-Licensing